Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer

European Respiratory Journal

Volumn 41, Issue 5, 2013, Pages 1172-1178

  Campayo, Marc ^a   Navarro, Alfons ^b   Vinõlas, Nuria ^a   Diaz, Tania ^b   Tejero, Rut ^b   Gimferrer, Josep M ^a   Molins, Laureano ^a   Cabanas, Maria L ^b   Ramirez, Jose ^b   Monzo, Mariano ^b   Marrades, Ramon ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

miR 145; miR 367; Nonsmall cell lung cancer; p53 prognostic markers

Indexed keywords

MICRORNA; MICRORNA 145; MICRORNA 302; MICRORNA 367; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EXON; FEMALE; GENE CLUSTER; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; UPREGULATION;

MIR-145; MIR-367; NONSMALL CELL LUNG CANCER; P53; PROGNOSTIC MARKERS;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877099251     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00048712     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, et al. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360. (Pubitemid 38101630)
3. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-1721. (Pubitemid 38501140)
4. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597. (Pubitemid 41007845)
5. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727. (Pubitemid 44283661)
6. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043-5051.
7. Ellis P, Fagan BM, Magness ST, et al. SOX2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev Neurosci 2004; 26: 148-165. (Pubitemid 40867972)
8. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676. (Pubitemid 44233629)
9. Karoubi G, Cortes-Dericks L, Gugger M, et al. Atypical expression and distribution of embryonic stem cell marker, OCT4, in human lung adenocarcinoma. J Surg Oncol 2010; 102: 689-698.
10. Meng HM, Zheng P, Wang XY, et al. Overexpression of nanog predicts tumour progression and poor prognosis in colorectal cancer. Cancer Biol Ther 2010; 9: 295-302.
11. Sholl LM, Long KB, Hornick JL. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol 2010; 18: 55-61.
12. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41: 1238-1242.
13. McCaughan F, Pole JC, Bankier AT, et al. Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med 2010; 182: 83-91.
14. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumours. Nat Genet 2008; 40: 499-507. (Pubitemid 351601215)
15. Hussenet T, Dali S, Exinger J, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 2010; 5: e8960.
16. Lu Y, Futtner C, Rock JR, et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One 2010; 5: e11022.
17. Sholl LM, Barletta JA, Yeap BY, et al. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 2010; 34: 1193-1198.
18. Barroso-delJesus A, Romero-Lopez C, Lucena-Aguilar G, et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol 2008; 28: 6609-6619.
19. Card DA, Hebbar PB, Li L, et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol 2008; 28: 6426-6438.
20. Xu N, Papagiannakopoulos T, Pan G, et al. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009; 137: 647-658.
21. Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumour suppressor miR-145. Proc Natl Acad Sci USA 2009; 106: 3207-3212.
22. Navarro A, Marrades RM, Vinolas N, et al. MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology 2009; 76: 162-169.
23. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008; 14: 844-852. (Pubitemid 351574906)
24. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003; 43: 121-137. (Pubitemid 36715216)
25. Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature 2009; 460: 529-533.
26. Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998; 95: 379-391. (Pubitemid 28507326)
27. Kellner S, Kikyo N. Transcriptional regulation of the Oct4 gene, a master gene for pluripotency. Histol Histopathol 2010; 25: 405-412.
28. Lin SL, Chang DC, Chang-Lin S, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008; 14: 2115-2124.
29. Yin R, Zhang S, Wu Y, et al. microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncol Rep 2011; 25: 1747-1754.
30. Barroso-del Jesus A, Lucena-Aguilar G, Menendez P. The miR-302-367 cluster as a potential stemness regulator in ESCs. Cell Cycle 2009; 8: 394-398.
31. Xiang R, Liao D, Cheng T, et al. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer 2011; 104: 1410-1417.
32. Suh SO, Chen Y, Zaman MS, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 2011; 32: 772-778.
33. Kajstura J, Rota M, Hall SR, et al. Evidence for human lung stem cells. N Engl J Med 2011; 364: 1795-1806.